Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average - Here's What Happened

Key Points

• Tenax shares passed above its 200-day moving average (200‑day MA $11.59), trading as high as $14.08 and last at $13.97 on volume of 276,633 shares, a technical signal of strength.
• Analyst sentiment is broadly positive: multiple firms initiated or raised ratings (Cantor Fitzgerald overweight $35 PT, Guggenheim to $34, Lifesci strong-buy), leaving a consensus rating of "Moderate Buy" and an average price target of $29.67.
• Tenax beat the recent EPS estimate, reporting ($0.38) vs. consensus ($1.26) for the quarter, and several institutional investors have recently added or increased positions in the stock.

Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.59 and traded as high as $14.08. Tenax Therapeutics shares last traded at $13.97, with a volume of 276,633 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms recently commented on TENX. Cantor Fitzgerald began coverage on Tenax Therapeutics in a research note on Tuesday, March 17th. They issued an "overweight" rating and a $35.00 target price on the stock. Lifesci Capital raised Tenax Therapeutics to a "strong-buy" rating in a research note on Thursday, March 12th. William Blair reissued an "outperform" rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. Finally, Guggenheim upped their price target on shares of Tenax Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.67.

Tenax Therapeutics Stock Up 0.4%

The firm's 50-day simple moving average is $13.65 and its 200-day simple moving average is $11.59. The firm has a market capitalization of $240.28 million, a PE ratio of -10.50 and a beta of 1.19.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.88. On average, equities research analysts forecast that Tenax Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Institutional Trading of Tenax Therapeutics

A number of institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC purchased a new stake in shares of Tenax Therapeutics during the fourth quarter worth about $5,353,000. Siren L.L.C. boosted its holdings in shares of Tenax Therapeutics by 21.2% during the fourth quarter. Siren L.L.C. now owns 427,141 shares of the specialty pharmaceutical company's stock worth $5,207,000 after purchasing an additional 74,700 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Tenax Therapeutics during the third quarter worth about $2,680,000. Millennium Management LLC boosted its holdings in shares of Tenax Therapeutics by 34.2% during the third quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock worth $2,387,000 after purchasing an additional 79,998 shares during the period. Finally, Marshall Wace LLP boosted its holdings in shares of Tenax Therapeutics by 68.2% during the fourth quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company's stock worth $3,634,000 after purchasing an additional 120,944 shares during the period. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company's proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax's lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.